(3 minutes read)
Zimbabwe has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention. It is the first country in Africa to give approval to the injectable preventive medicine
Zimbabwe has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention. It is the first country in Africa to give approval to injectable preventive medicine.
According to the World Health Organisation (WHO), CAB-LA may be offered to people at substantial risk of HIV acquisition as part of comprehensive HIV prevention approaches. They include sex workers and LGBTQIA+ communities. WHO advised countries to take up this initiative after observing a surge in new HIV infections globally.
Read Also:
https://trendsnafrica.com/zimbabwe-seeks-royalties-in-refined-metal/
https://trendsnafrica.com/imf-team-in-zimbabwe-to-take-stock-of-economic-challenges/
https://trendsnafrica.com/zimbabwe-to-focus-on-cotton-production/
Research carried out revealed that CAB-LA injections every two months were safe, well-tolerated, and highly effective in reducing the risk of HIV acquisition. The United Nations Population Fund (UNFPA) is one of the organisations involved in Zimbabwe’s HIV/Aids battle.
